The Cancer Advisor

Keytruda - $29.5 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion Verzenio - $4 billion Imfinzi - $4 billion Ibrance - $3 billion Tecentriq - $3 billion In the rapidly evolving field of oncology, several cancer drugs have become best-sellers due to their proven effectiveness against various cancer types. Below, we examine some of the top-selling cancer drugs, highlighting their FDA-approved indications, mechanisms of action, and sales figures. 1. Keytruda (Pembrolizumab) - $29.5 billion Keytruda is the world's bestselling cancer drug by a large margin. (Merck & Co.) Company: Merck & Co. 2024 sales: $29.5 billion Indications Approved by FDA: Melanoma,  ( KEYNOTE-006 and KEYNOTE-054 trials) Non-small cell lung cancer,  ( KEYNOTE-010, KEYNOTE-407, KEYNOTE-189, KEYNOTE 671 trials) head and neck cancer,  ( KEYNOTE-012 and KEYNOTE-048) kidney cancer (renal cell carcinoma),  ( KEYNOTE-426) classical ...

Cancer treatment is entering a bold new era, with 2025 shaping up to be a year of breakthroughs, hope, and innovation. Despite trillions spent on cancer research , cancer still kills around 10 million people a year and is a leading cause of death globally, according to the World Health Organization. Cancer research continues to advance at an unprecedented pace, with new treatments offering hope to millions of patients worldwide. From next-generation immunotherapies to repurposed drugs, here are the top 10 emerging cancer therapies that are changing the game—and could redefine survival for millions. 1. Next-Generation Immunotherapy Perhaps the most transformative breakthrough in modern oncology has been the rise of immunotherapy—a set of treatments that awaken the immune system to recognize and attack cancer cells. It is an idea as beautiful as it is powerful: train the body to see the enemy hiding in plain sight. Checkpoint inhibitors were the first major triumph in this domain. Cance...